AR065133A1 - Derivados de tetrahidroisoquinolina, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir enfermedades o trastornos asociados a la actividad de gpr119, tales como diabetes, obesidad y trastornos cardiovasculares, entre otros. - Google Patents
Derivados de tetrahidroisoquinolina, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir enfermedades o trastornos asociados a la actividad de gpr119, tales como diabetes, obesidad y trastornos cardiovasculares, entre otros.Info
- Publication number
- AR065133A1 AR065133A1 ARP080100423A ARP080100423A AR065133A1 AR 065133 A1 AR065133 A1 AR 065133A1 AR P080100423 A ARP080100423 A AR P080100423A AR P080100423 A ARP080100423 A AR P080100423A AR 065133 A1 AR065133 A1 AR 065133A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- halo
- substituted
- aryl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/08—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with a hetero atom directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Data Exchanges In Wide-Area Networks (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicacion 1: Un compuesto de formula (1) en la cual: B se selecciona de arilo C6-10, heteroarilo C1-10 cicloalquilo C3-12 y heterocicloalquilo C3-8; donde dicho arilo, heteroarilo, cicloalquilo o heterocicloalquilo de B está sustituido con uno a tres radicales seleccionados de -R3 y -OXaR3; donde Xa se selecciona de un enlace y alquileno C1-3; y donde cualquier heterocicloalquilo de B puede tener a CH2 grupo reemplazado con C(O); n y p se seleccionan independientemente de 0, 1, 2 y 3; q se selecciona de 0, 1 y 2; m se selecciona de 1, 2 y 3; L es -X1-A-X2-B1-X3-; donde A y B1 se seleccionan independientemente de un enlace, -O-, -S(O)0-2-, -C(O)-, -C(O)O-, -OC(O)-, -NR4-, -C(O)NR4-, -C(S)NR4, -NR4C(O)-, -CR4(NR4C(O)R4)-, -C(=NOR4)-, -CR4(NR4R4)-, -CR4(OR4)-, -CR4R4C(O)OR4-, -N(C(O)R4)- y -NR4C(S)-; donde X1, X2 y X3 se seleccionan independientemente de un enlace, alquileno C1-6, alquenileno C2-6, cicloalquilo C3-8, arilo C6-10, heterocicloalquilo C3-8 y heteroarileno C1-6; donde dicho cicloalquilo, arilo, heterocicloalquilo o heteroarilo de L pueden estar opcionalmente sustituidos con hasta 3 radicales independientemente seleccionados de hidroxilo, halo, alquilo C1-6, alcoxi C1-6, alquilo C1-6 sustituido con halo y alcoxi C1-6 sustituido con halo; cada R4 se selecciona independientemente de hidrogeno, hidroxilo, halo, alquilo C1-6, alquilo C1-6 sustituido con halo y alcoxi C1-6 sustituido con halo; con la condicion de que cuando A y B sean el mismo resto, X2 no puede ser un enlace; donde cualquier metileno de L puede tener los hidrogenos reemplazados por un radical seleccionado de halo, hidroxi, alquilo C1-4, alcoxi C1-4, alquilo C1-4 sustituido con hidroxi, -CR4R4C(O)OR4, -X4OR4a, -X4NR4aR4a, - X4NR4aX4OR4a, -X4C(O)OR4a y -X4C(O)R4a donde X4 se selecciona de un enlace y alquileno C1-4; R4a se selecciona de hidrogeno y alquilo C1-4; R1 se selecciona de alquilo C1-10, alquilo C1-10 sustituido con halo, arilo C6-10, heteroarilo C1-10, -S(O)0- 2R5a, -C(O)OR5a, -C(O)R5a, y -C(O)NR5aR5b; donde R5a y R5b se seleccionan independientemente de hidrogeno, alquilo C1-6, cicloalquilo C3-12, alquilo C1-6 sustituido con halo, arilo C6-10-alquilo C0-4 y heteroarilo C1-10; donde dicho alquilo, cicloalquilo, arilo o heteroarilo de R5a o R5b pueden estar opcionalmente sustituidos con 1 a 3 radicales independientemente seleccionados de hidrogeno, hidroxi, alquilo C1-6, alquenilo C2-6, alquilo C1-6 sustituido con halo, alcoxi C1-6 sustituido con halo, -NR5cR5d, -C(O)OR5c y arilo C6-10-alquilo C0-4 donde R5c y R5d se seleccionan independientemente de hidrogeno y alquilo C1-6; R2a y R2b se seleccionan independientemente de halo, ciano, hidroxi, alquilo C1-4, amino, nitro, -C(O)OR5e, - C(O)R5e y -NR5eR5f donde R5e y R5f se seleccionan independientemente de hidrogeno, alquilo C1-6, cicloalquilo C3-12, alquilo C1-6 sustituido con halo, cicloalquilo C1-6 sustituido con halo, arilo C6-10 y heteroarilo C1-10; donde dicho arilo o heteroarilo de R5e o R5f pueden estar opcionalmente sustituidos con 1 a 3 radicales independientemente seleccionados de alquilo C1-6, alcoxi C1-6, alquilo C1-6 sustituido con halo y alcoxi C1-6 sustituido con halo; R3 se selecciona de hidrogeno, heteroarilo C1-10, arilo C6-10, heterocicloalquilo C3-8, -C(O)OR6a, -C(O)R6a, -S(O)0-2R6a, -C(O)R7, -C(O)X5NR6aC(O)OR6b, -C(S)OR6a, -C(S)R6a, -C(S)R7 y -C(S)X5NR6aC(O)OR6b; donde X5 se selecciona de un enlace y alquileno C1-6; R6a y R6b se seleccionan independientemente de hidrogeno, alquilo C1-6, alquilo C1-6 sustituido con halo, cicloalquilo C3-12 opcionalmente sustituido con alquilo C1-4, cicloalquilo C1-6 sustituido con halo; R7 se selecciona de alquilo C1-8, cicloalquilo C3-8, arilo C6-10, heteroarilo C1-10 alquilo C1-8 sustituido con halo, cicloalquilo C3-8 sustituido con halo, arilo C6-10 sustituido con halo y heteroarilo C6-10 sustituido con halo; donde dicho arilo, heteroarilo o heterocicloalquilo de R3 está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados de halo, ciano, -X5aNR8aR8b, -X5aNR8aR9, -X5aNR8aC(O)OR8b, -X5aC(O)OR8a, -X5aOR8a, -X5aOX5bOR8a, -X5aC(O)R8a, -X5aR9, alquilo C1-6, alcoxi C1-6, alquilo C1-6 sustituido con halo y alcoxi C1-6 sustituido con halo; donde R8a y R8b se seleccionan independientemente de hidrogeno y alquilo C1-6; X5a y X5b se seleccionan independientemente de un enlace y alquileno C1-4; R9 se selecciona de cicloalquilo C3-12, heterocicloalquilo C3-8, heteroarilo C1-10 y arilo C6-10; donde dicho arilo, heteroarilo, cicloalquilo o heterocicloalquilo de R9 está opcionalmente sustituido con 1 a 3 radicales independientemente seleccionados de halo, alquilo C1-4 y alcoxi C1-4; o sus sales aceptables para uso farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88803307P | 2007-02-02 | 2007-02-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR065133A1 true AR065133A1 (es) | 2009-05-20 |
Family
ID=39356580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080100423A AR065133A1 (es) | 2007-02-02 | 2008-02-01 | Derivados de tetrahidroisoquinolina, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir enfermedades o trastornos asociados a la actividad de gpr119, tales como diabetes, obesidad y trastornos cardiovasculares, entre otros. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20080186971A1 (es) |
EP (1) | EP2114890A2 (es) |
JP (1) | JP2010518001A (es) |
KR (1) | KR20090114428A (es) |
CN (1) | CN101663278A (es) |
AR (1) | AR065133A1 (es) |
AU (1) | AU2008214440A1 (es) |
BR (1) | BRPI0808192A2 (es) |
CA (1) | CA2677263A1 (es) |
CL (1) | CL2008000316A1 (es) |
EA (1) | EA200901032A1 (es) |
MX (1) | MX2009008159A (es) |
PE (1) | PE20090057A1 (es) |
TW (1) | TW200836736A (es) |
WO (1) | WO2008097428A2 (es) |
Families Citing this family (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8799466B2 (en) * | 2005-01-31 | 2014-08-05 | Hewlett-Packard Development Company, L.P. | Method and apparatus for automatic verification of a network access control construct for a network switch |
WO2008008895A1 (en) * | 2006-07-13 | 2008-01-17 | Smithkline Beecham Corporation | Gpr119 agonists for the treatment of diabetes and related disorders |
US9045442B2 (en) | 2007-12-21 | 2015-06-02 | University Of Notre Dame Du Lac | Antibacterial compounds and methods of using same |
JP2011513233A (ja) * | 2008-02-22 | 2011-04-28 | アイアールエム・リミテッド・ライアビリティ・カンパニー | Gpr119活性モジュレーターとしての化合物および組成物 |
US8346697B2 (en) * | 2008-10-31 | 2013-01-01 | International Business Machines Corporation | Direct construction of finite state machines |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
JP5332854B2 (ja) * | 2009-04-20 | 2013-11-06 | ソニー株式会社 | 無線送信機、無線送信方法、無線受信機および無線受信方法 |
KR20120046188A (ko) | 2009-06-24 | 2012-05-09 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 신규 화합물, 약제학적 조성물 및 이에 관련된 방법 |
AR077214A1 (es) | 2009-06-24 | 2011-08-10 | Neurocrine Biosciences Inc | Heterociclos nitrogenados y composiciones farmaceuticas que los contienen |
CA2766088C (en) | 2009-06-25 | 2017-06-13 | Alkermes, Inc. | Heterocyclic compounds for the treatment of neurological and psychological disorders |
CA2766033C (en) | 2009-06-25 | 2016-09-20 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
WO2011113947A1 (en) | 2010-03-18 | 2011-09-22 | Boehringer Ingelheim International Gmbh | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
TW201202230A (en) * | 2010-05-24 | 2012-01-16 | Mitsubishi Tanabe Pharma Corp | Novel quinazoline compound |
NZ604035A (en) | 2010-06-04 | 2015-02-27 | Albany Molecular Res Inc | Glycine transporter-1 inhibitors, methods of making them, and uses thereof |
EP2585066B1 (en) | 2010-06-24 | 2018-09-26 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
AU2011326071A1 (en) | 2010-11-08 | 2013-05-23 | Lycera Corporation | N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases |
EP4327872A2 (en) | 2011-03-18 | 2024-02-28 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
JP6047144B2 (ja) * | 2011-04-08 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 置換シクロプロピル化合物、このような化合物を含有する組成物および処置方法 |
US9110703B2 (en) * | 2011-06-07 | 2015-08-18 | Hewlett-Packard Development Company, L.P. | Virtual machine packet processing |
ES2715562T3 (es) | 2011-12-15 | 2019-06-04 | Alkermes Pharma Ireland Ltd | Profármacos de compuestos de amina secundaria |
CN102659675A (zh) * | 2011-12-27 | 2012-09-12 | 盛世泰科生物医药技术(苏州)有限公司 | 6-溴-2-甲基磺酰基-1,2,3,4,-四氢异喹啉的一种合成方法 |
ES2950418T3 (es) | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden alcohol bencílico |
ES2764383T3 (es) | 2012-03-19 | 2020-06-03 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de glicerol |
ES2765036T3 (es) | 2012-03-19 | 2020-06-05 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden esteres de ácidos grasos |
JP5987901B2 (ja) * | 2012-03-30 | 2016-09-07 | 日本電気株式会社 | 制御装置、通信装置、通信方法及びプログラム |
EP2834226B1 (en) | 2012-04-04 | 2016-05-25 | F.Hoffmann-La Roche Ag | 1,2-pyridazine, 1,6-pyridazine or pyrimidine-benzamide derivatives as gpbar1 modulators |
AU2013259624B2 (en) | 2012-05-08 | 2017-10-19 | Lycera Corporation | Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
RU2014149136A (ru) | 2012-05-08 | 2016-07-10 | Мерк Шарп И Доум Корп. | ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ |
EP2872127A1 (en) | 2012-07-11 | 2015-05-20 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
WO2014080285A2 (en) | 2012-09-19 | 2014-05-30 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
US20140379915A1 (en) * | 2013-06-19 | 2014-12-25 | Cisco Technology, Inc. | Cloud based dynamic access control list management architecture |
KR101984281B1 (ko) * | 2013-08-08 | 2019-05-31 | 동아에스티 주식회사 | Gpr119 작용 활성을 갖는 신규 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
EP3071205B1 (en) | 2013-11-18 | 2020-02-05 | Forma Therapeutics, Inc. | Benzopiperazine compositions as bet bromodomain inhibitors |
JP6553632B2 (ja) | 2013-11-18 | 2019-07-31 | フォーマ セラピューティクス,インコーポレイテッド | Betブロモドメイン阻害剤としてのテトラヒドロキノリン組成物 |
US9783511B2 (en) | 2013-12-20 | 2017-10-10 | Lycera Corporation | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease |
WO2015095795A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE |
US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
AU2015222917A1 (en) | 2014-02-27 | 2016-09-15 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
US9452131B2 (en) | 2014-03-20 | 2016-09-27 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
US10189777B2 (en) | 2014-05-05 | 2019-01-29 | Lycera Corporation | Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease |
EP3140291A4 (en) | 2014-05-05 | 2018-01-10 | Lycera Corporation | Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease |
AU2015295405B2 (en) | 2014-08-01 | 2020-04-09 | Nuevolution A/S | Compounds active towards bromodomains |
CN108463459A (zh) | 2014-09-25 | 2018-08-28 | 圣母大学 | 非β-内酰胺类抗生素 |
CN104447693B (zh) * | 2014-10-24 | 2016-08-24 | 苏州昊帆生物科技有限公司 | 喹啉酮衍生物及其制备方法和应用 |
CN104592215A (zh) * | 2015-01-19 | 2015-05-06 | 湖南华腾制药有限公司 | 一种哌啶取代恶二唑衍生物的制备方法 |
WO2016130818A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
CN104610393A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途 |
CN104610390A (zh) * | 2015-02-13 | 2015-05-13 | 佛山市赛维斯医药科技有限公司 | 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途 |
CN104876918A (zh) * | 2015-04-23 | 2015-09-02 | 湖南华腾制药有限公司 | 一种吡嗪取代恶二唑化合物的制备方法 |
CN104788386A (zh) * | 2015-04-24 | 2015-07-22 | 湖南华腾制药有限公司 | 一种含氟嘧啶化合物的制备方法 |
AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
JP6838004B2 (ja) | 2015-06-11 | 2021-03-03 | リセラ・コーポレイションLycera Corporation | RORγのアゴニストとしての使用及び疾患の治療のためのアリールジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物 |
CN105175401A (zh) * | 2015-10-16 | 2015-12-23 | 北京康立生医药技术开发有限公司 | 一种依匹哌唑的制备方法 |
WO2017075178A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
MX2018005004A (es) | 2015-10-27 | 2018-09-12 | Merck Sharp & Dohme | Compuestos de indazol substituidos como inhibidores de rorgammat y sus usos. |
AU2016344118A1 (en) | 2015-10-27 | 2018-05-10 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
WO2018049404A1 (en) | 2016-09-12 | 2018-03-15 | University Of Notre Dame Du Lac | Compounds for the treatment of clostridium difficile infection |
US10341242B2 (en) * | 2016-12-13 | 2019-07-02 | Oracle International Corporation | System and method for providing a programmable packet classification framework for use in a network device |
US10404594B2 (en) | 2016-12-13 | 2019-09-03 | Oracle International Corporation | System and method for providing partitions of classification resources in a network device |
WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
WO2019079578A1 (en) | 2017-10-19 | 2019-04-25 | Amgen Inc. | BENZIMIDAZOLE DERIVATIVES AND USES THEREOF |
PT3710438T (pt) | 2017-12-19 | 2021-11-22 | Bristol Myers Squibb Co | Ácidos carbamoil ciclohexílicos n-ligados a triazol como antagonistas de lpa |
SG11202005698XA (en) | 2017-12-19 | 2020-07-29 | Bristol Myers Squibb Co | Cyclohexyl acid triazole azines as lpa antagonists |
JP7280881B2 (ja) | 2017-12-19 | 2023-05-24 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのシクロヘキシル酸トリアゾールアゾール |
US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
ES2948793T3 (es) | 2018-09-18 | 2023-09-19 | Bristol Myers Squibb Co | Acidos cicloheptílicos como antagonistas de LPA |
US20220041565A1 (en) | 2018-09-18 | 2022-02-10 | Bristol-Myers Squibb Company | Cyclopentyl acids as lpa antagonists |
US20210317131A1 (en) | 2018-09-18 | 2021-10-14 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
KR102661806B1 (ko) * | 2018-11-27 | 2024-04-30 | 삼성전자주식회사 | 디스플레이 장치의 제어 방법 및 그에 따른 디스플레이 장치 |
JP2022515990A (ja) * | 2018-12-10 | 2022-02-24 | ドライブネッツ リミテッド | 通信ネットワークにおけるトラフィックフローをモニタリングするシステム及び方法 |
CN109761990B (zh) * | 2019-01-30 | 2019-12-24 | 江西中医药大学 | 一种嘧啶并嘧啶类衍生物及其制备方法和在医药上的应用 |
JP7465898B2 (ja) | 2019-06-18 | 2024-04-11 | ブリストル-マイヤーズ スクイブ カンパニー | Lpaアンタゴニストとしてのトリアゾールカルボン酸 |
WO2020257139A1 (en) | 2019-06-18 | 2020-12-24 | Bristol-Myers Squibb Company | Cyclobutyl carboxylic acids as lpa antagonists |
BR112022023359A2 (pt) | 2020-05-19 | 2023-04-18 | Kallyope Inc | Ativadores de ampk |
AU2021275118A1 (en) | 2020-05-22 | 2022-12-01 | Aligos Therapeutics, Inc. | Methods and compositions for targeting PD-L1 |
CN116390925A (zh) | 2020-06-26 | 2023-07-04 | 卡尔优普公司 | Ampk活化剂 |
WO2022040002A1 (en) | 2020-08-17 | 2022-02-24 | Aligos Therapeutics, Inc. | Methods and compositions for targeting pd-l1 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859051A (en) * | 1996-02-02 | 1999-01-12 | Merck & Co., Inc. | Antidiabetic agents |
DE69731003D1 (de) * | 1996-07-01 | 2004-11-04 | Lilly Co Eli | Blutzuckersenkende und lipidsenkende verbindungen |
US5912342A (en) * | 1997-08-12 | 1999-06-15 | Heinonen; Petri | Compounds a containing a solid support |
US5995971A (en) * | 1997-09-18 | 1999-11-30 | Micdrosoft Corporation | Apparatus and accompanying methods, using a trie-indexed hierarchy forest, for storing wildcard-based patterns and, given an input key, retrieving, from the forest, a stored pattern that is identical to or more general than the key |
EP0937723A1 (de) * | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Sulfonamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
PL343424A1 (en) * | 1998-04-10 | 2001-08-13 | Japan Tobacco Inc | Amidine compounds |
US6658002B1 (en) * | 1998-06-30 | 2003-12-02 | Cisco Technology, Inc. | Logical operation unit for packet processing |
GB9816984D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Plc | Novel compounds |
US6643260B1 (en) * | 1998-12-18 | 2003-11-04 | Cisco Technology, Inc. | Method and apparatus for implementing a quality of service policy in a data communications network |
US6651096B1 (en) * | 1999-04-20 | 2003-11-18 | Cisco Technology, Inc. | Method and apparatus for organizing, storing and evaluating access control lists |
JP2001247569A (ja) * | 1999-08-12 | 2001-09-11 | Japan Tobacco Inc | ピロリジン誘導体又はピペリジン誘導体及びその医薬用途 |
US7028096B1 (en) * | 1999-09-14 | 2006-04-11 | Streaming21, Inc. | Method and apparatus for caching for streaming data |
US7058728B1 (en) * | 1999-10-29 | 2006-06-06 | Nokia Corporation | Method and apparatus for initiating compression of headers of packets and refreshing the context related to the packets |
CA2324801A1 (en) * | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Use of apo b secretion/mtp inhibitors and anti-obesity agents |
AU782631C (en) * | 1999-12-03 | 2006-08-17 | Kyoto Pharmaceutical Industries, Ltd. | Novel heterocyclic compounds and salts thereof and medicinal use of the same |
US6798746B1 (en) * | 1999-12-18 | 2004-09-28 | Cisco Technology, Inc. | Method and apparatus for implementing a quality of service policy in a data communications network |
US6977930B1 (en) * | 2000-02-14 | 2005-12-20 | Cisco Technology, Inc. | Pipelined packet switching and queuing architecture |
WO2001087834A1 (fr) * | 2000-05-16 | 2001-11-22 | Takeda Chemical Industries, Ltd. | Antagoniste de l'hormone de concentration de la melanine |
US7050430B2 (en) * | 2000-06-09 | 2006-05-23 | Broadcom Corporation | Gigabit switch with fast filtering processor |
US6658458B1 (en) * | 2000-06-22 | 2003-12-02 | Cisco Technology, Inc. | Cascading associative memory arrangement |
US7051078B1 (en) * | 2000-07-10 | 2006-05-23 | Cisco Technology, Inc. | Hierarchical associative memory-based classification system |
US6952425B1 (en) * | 2000-11-14 | 2005-10-04 | Cisco Technology, Inc. | Packet data analysis with efficient and flexible parsing capabilities |
US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7096256B1 (en) * | 2001-02-26 | 2006-08-22 | Juniper Network, Inc. | Applying configuration group information to target configuration information |
CA2441080A1 (en) * | 2001-03-23 | 2002-10-03 | Eli Lilly And Company | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses |
US7002965B1 (en) * | 2001-05-21 | 2006-02-21 | Cisco Technology, Inc. | Method and apparatus for using ternary and binary content-addressable memory stages to classify packets |
US7065083B1 (en) * | 2001-10-04 | 2006-06-20 | Cisco Technology, Inc. | Method and apparatus for dynamically generating lookup words for content-addressable memories |
US6775737B1 (en) * | 2001-10-09 | 2004-08-10 | Cisco Technology, Inc. | Method and apparatus for allocating and using range identifiers as input values to content-addressable memories |
US7133914B1 (en) * | 2001-10-31 | 2006-11-07 | Cisco Technology, Inc. | Statistics-preserving ACL flattening system and method |
US7224968B2 (en) * | 2001-11-23 | 2007-05-29 | Actix Limited | Network testing and monitoring systems |
US6957215B2 (en) * | 2001-12-10 | 2005-10-18 | Hywire Ltd. | Multi-dimensional associative search engine |
US7067517B2 (en) * | 2001-12-14 | 2006-06-27 | Nero Nordisk A/S | Use of compounds for decreasing activity of hormone-sensitive lipase |
US6715029B1 (en) * | 2002-01-07 | 2004-03-30 | Cisco Technology, Inc. | Method and apparatus for possibly decreasing the number of associative memory entries by supplementing an associative memory result with discriminator bits from an original set of information |
US6970971B1 (en) * | 2002-01-08 | 2005-11-29 | Cisco Technology, Inc. | Method and apparatus for mapping prefixes and values of a hierarchical space to other representations |
US7154888B1 (en) * | 2002-02-08 | 2006-12-26 | Cisco Technology, Inc. | Method for classifying packets using multi-class structures |
AU2003245773A1 (en) * | 2002-02-15 | 2003-09-04 | Glaxo Group Limited | Vanilloid receptor modulators |
US6871265B1 (en) * | 2002-02-20 | 2005-03-22 | Cisco Technology, Inc. | Method and apparatus for maintaining netflow statistics using an associative memory to identify and maintain netflows |
WO2003075921A2 (en) * | 2002-03-05 | 2003-09-18 | Transtech Pharma, Inc. | Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage |
GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
US6867991B1 (en) * | 2003-07-03 | 2005-03-15 | Integrated Device Technology, Inc. | Content addressable memory devices with virtual partitioning and methods of operating the same |
US7236493B1 (en) * | 2002-06-13 | 2007-06-26 | Cisco Technology, Inc. | Incremental compilation for classification and filtering rules |
US7065367B2 (en) * | 2002-07-11 | 2006-06-20 | Oliver Michaelis | Interface selection in a wireless communication network |
US7028136B1 (en) * | 2002-08-10 | 2006-04-11 | Cisco Technology, Inc. | Managing idle time and performing lookup operations to adapt to refresh requirements or operational rates of the particular associative memory or other devices used to implement the system |
US7065609B2 (en) * | 2002-08-10 | 2006-06-20 | Cisco Technology, Inc. | Performing lookup operations using associative memories optionally including selectively determining which associative memory blocks to use in identifying a result and possibly propagating error indications |
US7103708B2 (en) * | 2002-08-10 | 2006-09-05 | Cisco Technology, Inc. | Performing lookup operations using associative memories optionally including modifying a search key in generating a lookup word and possibly forcing a no-hit indication in response to matching a particular entry |
US7082492B2 (en) * | 2002-08-10 | 2006-07-25 | Cisco Technology, Inc. | Associative memory entries with force no-hit and priority indications of particular use in implementing policy maps in communication devices |
EP1562595B1 (en) * | 2002-09-19 | 2008-05-21 | Eli Lilly And Company | Diaryl ethers as opioid receptor antagonists |
EP1546145A1 (en) * | 2002-09-26 | 2005-06-29 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
US7093092B2 (en) * | 2002-12-10 | 2006-08-15 | Isic Corporation | Methods and apparatus for data storage and retrieval |
US7468979B2 (en) * | 2002-12-20 | 2008-12-23 | Force10 Networks, Inc. | Layer-1 packet filtering |
US7043494B1 (en) * | 2003-01-28 | 2006-05-09 | Pmc-Sierra, Inc. | Fast, deterministic exact match look-ups in large tables |
WO2004078176A1 (en) * | 2003-03-03 | 2004-09-16 | F. Hoffmann-La Roche Ag | 2,5- and 2,6-substituted tetrahydroisoquinolines for use as 5-ht6 modulators |
CN102174042B (zh) * | 2003-05-19 | 2013-09-18 | Irm有限责任公司 | 免疫抑制剂化合物和组合物 |
US7313827B2 (en) * | 2003-07-10 | 2007-12-25 | International Business Machines Corporation | Apparatus and method for analysis of conversational patterns to position information and autonomic access control list management |
US20050114700A1 (en) * | 2003-08-13 | 2005-05-26 | Sensory Networks, Inc. | Integrated circuit apparatus and method for high throughput signature based network applications |
US7080195B2 (en) * | 2003-10-22 | 2006-07-18 | Cisco Technology, Inc. | Merging indications of matching items of multiple groups and possibly associated with skip conditions to identify winning entries of particular use for implementing access control lists |
EP1701954A1 (en) * | 2003-12-31 | 2006-09-20 | Warner-Lambert Company LLC | N-substituted piperidine and piperazine derivatives |
US7356663B2 (en) * | 2004-11-08 | 2008-04-08 | Intruguard Devices, Inc. | Layered memory architecture for deterministic finite automaton based string matching useful in network intrusion detection and prevention systems and apparatuses |
CA2592118C (en) * | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
EP1849093A2 (en) * | 2005-01-06 | 2007-10-31 | Tervela Inc. | Hardware-based messaging appliance |
TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
US8980915B2 (en) * | 2005-04-19 | 2015-03-17 | Surface Logix, Inc. | Inhibitors of microsomal triglyceride transfer protein and apo-B secretion |
MX2007014180A (es) * | 2005-05-10 | 2008-01-14 | Vertex Pharma | Derivados biciclicos como moduladores de canales de iones. |
WO2007050124A1 (en) * | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
TWI329641B (en) * | 2005-08-31 | 2010-09-01 | Otsuka Pharma Co Ltd | (benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same |
US7499941B2 (en) * | 2005-09-05 | 2009-03-03 | Cisco Technology, Inc. | Pipeline regular expression matching |
US7790745B2 (en) * | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
TW200800220A (en) * | 2005-10-26 | 2008-01-01 | Boehringer Ingelheim Int | New (hetero)aryl compounds with MCH antagonistic activity and medicaments comprising these compounds |
US8589574B1 (en) * | 2005-12-29 | 2013-11-19 | Amazon Technologies, Inc. | Dynamic application instance discovery and state management within a distributed system |
WO2008021849A2 (en) * | 2006-08-09 | 2008-02-21 | Smithkline Beecham Corporation | Novel compounds as antagonists or inverse agonists at opioid receptors |
JP2010500832A (ja) * | 2006-08-09 | 2010-01-07 | クゥアルコム・インコーポレイテッド | 簡易型ソケットインタフェースを経由する放送/同報ipパケットをサポートするための装置と方法 |
TW200825054A (en) * | 2006-10-18 | 2008-06-16 | Wyeth Corp | Quinoline compounds |
US7831607B2 (en) * | 2006-12-08 | 2010-11-09 | Pandya Ashish A | Interval symbol architecture for programmable intelligent search memory |
-
2007
- 2007-08-27 US US11/845,696 patent/US20080186971A1/en not_active Abandoned
-
2008
- 2008-01-22 EA EA200901032A patent/EA200901032A1/ru unknown
- 2008-01-22 CN CN200880010548A patent/CN101663278A/zh active Pending
- 2008-01-22 US US12/525,289 patent/US20100022515A1/en not_active Abandoned
- 2008-01-22 AU AU2008214440A patent/AU2008214440A1/en not_active Abandoned
- 2008-01-22 CA CA002677263A patent/CA2677263A1/en not_active Abandoned
- 2008-01-22 BR BRPI0808192A patent/BRPI0808192A2/pt not_active IP Right Cessation
- 2008-01-22 MX MX2009008159A patent/MX2009008159A/es not_active Application Discontinuation
- 2008-01-22 JP JP2009548265A patent/JP2010518001A/ja active Pending
- 2008-01-22 EP EP08713244A patent/EP2114890A2/en not_active Withdrawn
- 2008-01-22 KR KR1020097018273A patent/KR20090114428A/ko active IP Right Grant
- 2008-01-22 WO PCT/US2008/000864 patent/WO2008097428A2/en active Search and Examination
- 2008-01-31 PE PE2008000230A patent/PE20090057A1/es not_active Application Discontinuation
- 2008-02-01 CL CL200800316A patent/CL2008000316A1/es unknown
- 2008-02-01 TW TW097104093A patent/TW200836736A/zh unknown
- 2008-02-01 AR ARP080100423A patent/AR065133A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20090057A1 (es) | 2009-02-13 |
US20100022515A1 (en) | 2010-01-28 |
WO2008097428A3 (en) | 2008-09-25 |
BRPI0808192A2 (pt) | 2019-09-24 |
WO2008097428A2 (en) | 2008-08-14 |
CL2008000316A1 (es) | 2008-08-08 |
CN101663278A (zh) | 2010-03-03 |
CA2677263A1 (en) | 2008-08-14 |
JP2010518001A (ja) | 2010-05-27 |
EP2114890A2 (en) | 2009-11-11 |
AU2008214440A1 (en) | 2008-08-14 |
EA200901032A1 (ru) | 2010-02-26 |
TW200836736A (en) | 2008-09-16 |
MX2009008159A (es) | 2009-10-08 |
US20080186971A1 (en) | 2008-08-07 |
KR20090114428A (ko) | 2009-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR065133A1 (es) | Derivados de tetrahidroisoquinolina, composiciones farmaceuticas que los contienen y usos de los mismos para tratar o prevenir enfermedades o trastornos asociados a la actividad de gpr119, tales como diabetes, obesidad y trastornos cardiovasculares, entre otros. | |
AR070469A1 (es) | Derivados de naftiridina y composiciones farmaceuticas como inhibidores de quinasa con actividad sobre c- kit y pdgfr | |
AR077413A1 (es) | Derivados piridin-4-ilo | |
AR070925A1 (es) | 4- hidroxipirimidina -5- carboxamida sustituidas, un procedimiento para el tratamiento preventivo de anemia, procedimiento para potenciar la produccion endogena de eritropoyetina, uso del compuesto en la fabricacion de un medicamento y composicion farmaceutica | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR049711A1 (es) | Compuestos heterociclicos condensados como inhibidores de la aldosterona sintasa; composiciones farmaceuticas que los contienen y su uso en la preparacion de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el hiperaldosterismo y por una liberacion excesiva de cortiso | |
AR073138A1 (es) | Derivados de dioxa-biciclo (3.2.1) octano- 2,3,4-triol | |
AR079553A1 (es) | Derivados de diaza-espiro-[5,5]-undecanos, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos del snc, tales como trastornos del sueno y de la dependencia,entre otros. | |
AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
AR058073A1 (es) | Derivados de imidazol 5-il-pirimidina, procesos de obtencion, composiciones farmaceuticas y usos | |
CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
AR072906A1 (es) | Nucleosidos modificados utiles como antivirales | |
AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
AR074966A1 (es) | Compuestos amino-heterociclicos | |
AR041170A1 (es) | Derivados de bencimidazol, benzoxazol y benzotiazol | |
AR038240A1 (es) | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para su preparacion | |
AR050540A1 (es) | Derivados de adamantilamida triciclica como inhibidores de deshidrogenasa 11- beta hidroxiesteroide | |
AR061548A1 (es) | 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii. | |
AR075729A1 (es) | Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes. | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
AR076460A1 (es) | Antagonistas del receptor cxcr3 | |
AR048607A1 (es) | Derivados (poli)aminoalquilaminoacetamida de la epipodofilotoxina, proceso de preparacion de los mismos y sus aplicaciones terapeuticas como agentes anticancerosos | |
AR037534A1 (es) | Derivado de adamantano, su uso en la fabricacion de un medicamento para usar en terapia, composicion farmaceutica, proceso para la preparacion de dicho compuesto y dicha composicion y compuestos intermediarios | |
AR082844A1 (es) | Derivados de piperidina y su uso para el tratamiento de desordenes metabolicos | |
AR057906A1 (es) | Derivados de pirimidona biciclicos sustituidos y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad anormal de gsk3beta. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |